References
- 1. Jazwinski A B, Muir AJ. Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2011;7(3):154-162.
- 2. Kai TS. Expert Opinion. Pharmacotherapy. 2012;13(4):593-606
- 3. Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr top microbiol immunol. 2013;369:321-42.10.1007/978-3-642-27340-7_1323463207
- 4. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012;61 Suppl 1:i36-46.10.1136/gutjnl-2012-30214422504918
- 5. Casey LC, Lee W M. Hepatitis C Virus Therapy Update 2013. Curr Opin Gastroenterol. 2013;29(3):243-249.
- 6. Ghany M, Nelson D, Strader D, et al. AASLD Practice Guideline. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Disease. Hepatology 2011; 54:1433-1444.10.1002/hep.24641322984121898493
- 7. McHutchison J, Everson G, Gordon C, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.10.1056/NEJMoa080610419403902
- 8. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.10.1056/NEJMoa080765019403903
- 9. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.10.1056/NEJMoa101291221696307
- 10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-242810.1056/NEJMoa101308621696308